Immune Checkpoint Inhibitors Market 2025 to 2034
Immune Checkpoint Inhibitors Market 2025 to 2034
Immune Checkpoint Inhibitors Market (By Drug Type: CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor; By Disease Indication: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others; By End Users: Hospitals, Specialty Clinics, and Academic & Research Institutions; By Region: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
Customisation Request
Revenue, 2025
USD 58.53 Bn
Forecast Year, 2034
USD 229.60 Bn
CAGR, 2025 - 2034
16.40%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The immune checkpoint inhibitors market was valued at USD 58.53 billion in 2025 and is projected to reach about USD 229.60 billion by 2034, expanding at a strong CAGR of 16.40%, driven by rising cancer prevalence and advances in immuno-oncology.
Immune Checkpoint Inhibitors Market Size Analysis
Immune Checkpoint Inhibitors Market Size By Drug Type 2025 to 2034 (USD Billion)
| Drug Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| CTLA-4 Inhibitor | 12.88 | 14.85 | 17.13 | 19.75 | 22.78 | 26.26 | 30.28 | 34.91 | 40.24 | 46.38 |
| PD-1 Inhibitor | 28.09 | 32.91 | 38.54 | 45.14 | 52.87 | 61.91 | 72.50 | 84.89 | 99.41 | 116.40 |
| PD-L1 Inhibitor | 17.56 | 20.37 | 23.63 | 27.42 | 31.81 | 36.90 | 42.80 | 49.65 | 57.59 | 66.81 |
Immune Checkpoint Inhibitors Market Size By Disease Indication 2025 to 2034 (USD Billion)
| Disease Indication | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Lung Cancer | 22.24 | 26.03 | 30.45 | 35.63 | 41.69 | 48.78 | 57.07 | 66.76 | 78.11 | 91.38 |
| Bladder Cancer | 8.19 | 9.61 | 11.26 | 13.20 | 15.47 | 18.14 | 21.25 | 24.91 | 29.19 | 34.21 |
| Melanoma | 12.88 | 14.92 | 17.29 | 20.03 | 23.21 | 26.89 | 31.15 | 36.09 | 41.81 | 48.44 |
| Hodgkin lymphoma | 5.85 | 6.78 | 7.85 | 9.09 | 10.53 | 12.19 | 14.12 | 16.35 | 18.94 | 21.93 |
| Others | 9.36 | 10.80 | 12.45 | 14.35 | 16.55 | 19.07 | 21.98 | 25.33 | 29.19 | 33.63 |
Immune Checkpoint Inhibitors Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 25.75 | 29.84 | 34.57 | 40.06 | 46.42 | 53.78 | 62.31 | 72.19 | 83.63 | 96.89 |
| Europe | 15.22 | 17.65 | 20.46 | 23.72 | 27.51 | 31.89 | 36.98 | 42.87 | 49.70 | 57.63 |
| Asia Pacific | 11.71 | 13.83 | 16.34 | 19.29 | 22.78 | 26.89 | 31.74 | 37.45 | 44.18 | 52.12 |
| Latin America | 3.51 | 4.12 | 4.84 | 5.68 | 6.66 | 7.82 | 9.17 | 10.76 | 12.62 | 14.81 |
| Middle East and Africa | 2.34 | 2.76 | 3.25 | 3.83 | 4.51 | 5.32 | 6.26 | 7.37 | 8.68 | 10.22 |
Immune Checkpoint Inhibitors Market Size to Worth USD 229.60 Billion by 2034
The immune checkpoint inhibitors market size was evaluated at USD 58.53 bn in 2025 and is expected to grow around USD 229.60 bn by 2034 a CAGR of 16.40%.
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
